HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $119.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $137.00 | Outperform | RBC Capital Mkts |
| 1/28/2026 | $144.00 | Hold → Buy | HSBC Securities |
| 1/14/2026 | $131.00 | Buy → Hold | TD Cowen |
| 12/11/2025 | $176.00 | Buy | UBS |
| 7/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/9/2025 | $142.00 | Buy → Hold | HSBC Securities |
| 6/30/2025 | $150.00 | Overweight | Piper Sandler |
| 5/14/2025 | $150.00 | Equal-Weight → Overweight | Morgan Stanley |
DEFA14A - KKR & Co. Inc. (0001404912) (Filer)
SCHEDULE 13G/A - KKR & Co. Inc. (0001404912) (Subject)
DEFA14A - KKR & Co. Inc. (0001404912) (Filer)
RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00
HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00
TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Issuer)
PHILADELPHIA and NEW YORK, April 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its first quarter 2026 results after the close of trading on the New York Stock Exchange on Wednesday, May 6, 2026. FSK will host its first quarter 2026 results conference call via live webcast on Thursday, May 7, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the following URL
KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the first quarter 2026 on Tuesday, May 5, 2026, before the opening of trading on the New York Stock Exchange. A conference call to discuss KKR's financial results will be held on Tuesday, May 5, 2026 at 10:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be availab
KKR Tender Offer Receives Support from Taiyo Holdings' Board, Largest Shareholders and Founding Family KKR, a leading global investment firm, and Taiyo Holdings Co., Ltd. ("Taiyo Holdings" or the "Company"; TSE stock code 4626), announced today that KJ005 Co., Ltd. (the "Offeror"), an entity owned by investment funds managed by KKR, intends to make a tender offer to acquire all the common shares of Taiyo Holdings (the "Tender Offer"). Taiyo Holdings' Board of Directors has resolved to support the Tender Offer. In addition, DIC Corporation ("DIC"), Taiyo Holdings' largest shareholder, Kowa Co., Ltd. ("Kowa"), an asset management company affiliated with Taiyo Holdings' founding family, and
Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential
Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden
KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
Vertical Bridge REIT, LLC ("Vertical Bridge" or the "Company"), the largest private owner and operator of communications infrastructure in the United States, and leading global investment firm KKR today announced that KKR will make a $1.5 billion equity investment in the Company to support its future growth. The addition of KKR as a new investor establishes a fully funded, long‑term capital structure that supports Vertical Bridge's strategic plan and reinforces the Company's position as a permanent owner and operator of a nationwide portfolio of more than 17,000 towers. "This transaction provides us with the resources to continue developing our portfolio at scale while maintaining our d
HealthCare Royalty ("HCRx") today announced it has entered into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics Inc. securityholders for an undisclosed percentage of royalties on Modeyso® (dordaviprone) commercial sales. Modeyso received U.S. FDA accelerated approval in August 2025 for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is commercialized by Jazz Pharmaceuticals. "Since its launch in August, Modeyso has demonstrated strong early performance, reflecting the significant unmet need, high awareness
KKR to become active minority investor through KRW 1.22 trillion ($820 million) investment KKR, a leading global investment firm, and Samsung SDS, a leading enterprise IT solutions company (the "Company") and a member of Samsung Group, today announced a strategic partnership to support Samsung SDS' next phase of growth and long-term value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414166241/en/ Under the strategic partnership, KKR, through funds managed by KKR, and Samsung SDS will closely collaborate on a range of value creation initiatives for the Company, including supporting organic and inorganic growth st